Flash

Flash·2026-11-17 22:30

Isomorphic Labs Raises $5B Series C to Push AI-Designed Drugs Toward Trials

Isomorphic Labs, Alphabet's AI drug-discovery company, announced on Nov 17 a $5 billion Series C financing round co-led by Greenoaks and Sequoia Capital, with the funds going to advance its AI drug-design engine IsoDDE and move its first drug candidates toward clinical trials.

A bright modern biotech lab, a scientist examining a floating holographic molecular structure
AI-generated illustration

What happened

The round was oversubscribed and co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz and several other new investors joining and Alphabet making a further significant investment; every existing investor returned, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The company did not disclose a valuation.

Isomorphic Labs was spun out of Google DeepMind in 2021 and is headquartered in London, led by DeepMind co-founder Sir Demis Hassabis as CEO. The company said its drug-design engine IsoDDE unifies a suite of foundational simulation AI models spanning multiple therapeutic areas and drug modalities, searching chemical space to design and refine molecules while proprietary agents navigate and reason over complex biological systems. The company reported positive preclinical results from its wholly owned oncology and immunology programs and from partnered programs, setting the stage for clinical entry.

In the announcement, Hassabis said the drug design engine is generating molecules with unprecedented precision and speed, and that the round will accelerate building foundational biology models, deepening understanding of systemic disease and driving the first therapeutic programs toward clinical trials.

Key facts

  1. Round: $5 billion Series C, oversubscribed, co-led by Greenoaks and Sequoia Capital
  2. Investors: Andreessen Horowitz and other new investors joined; Alphabet made a significant further investment; all existing investors returned, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund
  3. Valuation: The company did not disclose a valuation for the round
  4. Engine: IsoDDE is the company's proprietary drug-design engine, a suite of foundational simulation AI models spanning multiple therapeutic areas and drug modalities
  5. Progress: Wholly owned oncology and immunology programs and partnered programs reported positive preclinical results; human trials have not yet begun
  6. Previous round: The previous round was a $2.1 billion Series B announced May 12, 2026, led by Thrive Capital
  7. Partners: Partners listed on the company's website include Novartis, Eli Lilly and Johnson & Johnson
  8. Use of proceeds: Proceeds will fund further development of IsoDDE, expansion into new areas of biology, a partner ecosystem for mechanistic disease biology, and AI-first translational and clinical development infrastructure

Why it matters

The $5 billion Series C comes about six months after a $2.1 billion Series B, and the money is aimed at moving AI-designed drug candidates into human trials; the company has not yet begun human trials, so clinical entry for its first candidates is the round's next test.
Useful Tap if this story helped you
Send to a friendMakes a share image for X, WeChat, Telegram and more

SourcesPR Newswire (Nov 17, 2026); Reuters (Nov 17, 2026). This article is compiled from public information and does not constitute investment advice.

From HIMIAO Horizon · himiao.ai

Grab todayOpenAI Codex for Students: $100 in Free CreditsHIMIAO Picks →

Follow HIMIAO Horizon

No sign-up · Unsubscribe any time

Email

Notifications

A ping on your phone or computer when the brief is out. No email needed.

HIMIAO PicksWeekly freebies: one email every Friday, a 5-minute read

Comments

  1. Loading comments…
Ask the cat